Billionaire investor Howard Marks, the co-chairman of Oaktree Capital, predicts there won't be a recession in the U.S. for another two years.US Economyread more
Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
Stocks in Asia Pacific edged up in Friday afternoon trade as a series of developments overnight on the U.S.-China trade front dampened hopes of a deal being reached between...Asia Marketsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
One person was killed and five others wounded on Thursday in a shooting on the streets of Washington, D.C., not far from the White House, police said.U.S. Newsread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
Asian cities are on the rise and are dominant in the Fintech space.Financeread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
(Adds details of rivalry, comment from Novartis)
ZURICH, Aug 30 (Reuters) - Swiss drugmaker Novartis on Friday threw down the gauntlet at Roche's multiple sclerosis franchise, touting study results for its MS hopeful ofatumumab that it hopes will muscle in on its crosstown rival's drug Ocrevus.
Novartis said ofatumumab, already approved as Arzerra to treat leukemia, demonstrated superiority versus Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). The results are due to be outlined at an MS conference in Sweden next month.
But Novartis's real target with ofatumumab is Ocrevus, the $2.4 billion-per-year MS blockbuster that Roche has branded its most successful drug launch ever. Novartis plans to start asking health authorities for approvals by year's end, it said.
Ofatumumab and Ocrevus work similarly by targeting the immune system's B cells that damage nerve tissue, putting the drugs on a collision course when doctors choose which medicine to prescribe. Novartis touts ofatumumab's monthly home injections as a convenient option for patients who with Ocrevus get twice-yearly infusions.
"If approved, ofatumumab will potentially become a treatment for a broad RMS population and the first B-cell therapy that can be self-administered at home," said Novartis, which is re-purposing Arzerra for MS as it seeks to strengthen its neurological drugs business, which already includes older MS drugs Gilenya and recently approved Mayzent.
Across the Rhine River from Novartis's Basel campus, Roche drugs division head Bill Anderson has countered Novartis's ofatumumab offensive with a "bring-it-on" approach of his own, suggesting twice-yearly infusions of Ocrevus, as opposed to monthly shots, result in deep B-cell depletions and robust benefits that have helped it capture 17% market share.
Anderson has bragged that since Novartis's Mayzent launch in March, Ocrevus has actually gained market share. (Reporting by John Miller; Editing by Michael Shields)